Against the background of the upsurge in interest in Alzheimer's disease driven by the recent controversial US approval of Biogen's Aduhelm, Muna Therapeutics has launched with an impressive $73m series A financing supported by a global syndicate of big name investors who are backing the Danish biotech's approach to slowing or stopping neurodegenerative diseases.
Muna, which means 'to remember' in old Norse, was founded in 2020 by Simon Glerup and his team from Aarhus...






